The prognosis of patients with renal cancer combined with lung metastasis is poor, and some studies claim that the 1-year progression-free survival rate after targeted therapy is about 30, which varies from person to person. Kidney cancer is one of the most common malignant tumors in the urinary system, and about 30% of patients have distant metastasis at the time of diagnosis. As metastatic renal cancer is not sensitive to traditional chemotherapeutic drugs and radiotherapy, the 5-year survival rate is less than 20%, and the median survival time is 7.8-43.2 months. Currently, targeted therapeutic agents (e.g. sorafenib) are widely used in the treatment of metastatic renal cancer, which effectively improves the prognosis of patients. Currently, the main target of targeted therapy is to inhibit pathways such as vascular endothelial growth factor receptor (VEGFR) or mammalian target of rapamycin (mTOR), and drugs targeting the VEGFR pathway (e.g., anti-angiogenic drugs such as sunitinib and pazopanib) have been used as a first-line therapeutic option for locally advanced or metastatic renal cancer. A study in China said that 1-year progression-free survival rate (without metastasis/recurrence, etc.) of patients with renal cancer combined with lung metastasis transference treated with apatinib is about 30%, and the median progression-free survival period is 9.5 months. In addition, in addition to targeted therapy, patients can also receive immunotherapy to improve their prognosis. It is recommended to go to a regular hospital to evaluate the condition, follow the doctor’s instructions to cooperate with the treatment, and strictly follow the doctor’s instructions for medication, do not use your own medication, so as to avoid delaying the condition.